August 10, 2018 10:55 AM EDT

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Brittany Meiling

→ Just a couple days after announcing some mixed pipeline updates that yo-yoed the stock, gene therapy company RegenXBio $RGNX is trotting out news …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Brittany Meiling

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage mi­to­chon­dr­i­al drug

Brittany Meiling

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After mixed pipeline updates, RegenXBio to raise $175M in offering; BioElectron closes $40M to prep late-stage mitochondrial drug

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?